(Q31521444)

2 July 2017

1 reference

title

Pharmacology and clinical experience with repaglinide (English)

1 reference

2 July 2017

1 reference

Massi-Benedetti M

1

1 reference

PubMed ID

11060717

2 July 2017

Damsbo P

series ordinal

2

1 reference

PubMed ID

11060717

2 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

Expert Opinion on Investigational Drugs

2 July 2017

1 reference

2 July 2017

9

1 reference

2 July 2017

4

1 reference

2 July 2017

885-898

1 reference

Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance.

2 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Benefits and Risks With Glyburide and Glipizide in Elderly NIDDM Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Repaglinide pharmacokinetics in healthy young adult and elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

Repaglinide versus glyburide: a one-year comparison trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.9.4.885

21 January 2018

Identifiers

DOI

10.1517/13543784.9.4.885

1 reference

2 July 2017

1 reference

PubMed ID

11060717